Pharmacodynamics: Change in 
In the double‐blind phase, administration of batoclimab at both doses was associated with decreases in serum concentrations of total IgG that were significantly different (Serum total IgG levels over time. IgG, immunoglobulin G; OLE, open‐label extension; q2w, once every 2 weeks; qw, once weekly; SD, standard deviation.Reductions in IgG subclasses (1–4) with batoclimab were generally consistent with total IgG during the double‐blind phase. Percentage changes from baseline to 6 weeks post‐baseline (mean [±SD]) for the combined batoclimab arm versus the placebo arm were as follows: IgG1, −71.5% (±9.9%) versus −2.1% (±8.7%); IgG2, −61.0% (±13.7%) versus −2.3% (±3.2%); IgG3, −76.1% (±11.5%) versus 1.2% (±14.4%); and IgG4, −55.6% (±16.8%) versus −4.9% (±9.8%). Batoclimab administration had no observable effects on serum IgA and IgM concentrations (data not shown). Serum anti‐AChR antibody concentrations also declined significantly in the batoclimab arms (340 mg: Serum anti‐AChR antibodies over time. AChR, acetylcholine receptor; OLE, open‐label extension; q2w, once every 2 weeks; qw, once weekly; SD, standard deviation.